Fixed price, unfixed volume: the company is locked into a rate while the amount it can sell against it is climbing
The model's full reasoning — Q4 2022 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management describe a situation where the price/rate/fee is already fixed or contractually set, while the quantity of business at that rate is currently rising or about to rise, so that results scale with volume added, not price negotiated? We need to find a coherent situation with both halves: (1) rate side settled, (2) volume side open and moving up now, and management conveys that reported results reflect lower volume, so step-up is meaningful. Look at the transcript. Management discusses various programs. Key points: They have partnerships with five companies, expect milestone payments. They sold royalty rights to Royalty Pharma for $250M upfront plus up to $160M contingent. They retained $400M in milestones from Amgen. But that's not a per-unit rate. They have 20 in '25 program: 20 drug candidates in clinical trials or market by 2025. That's about pipeline expansion, not necessarily a fixed rate per unit. They discuss ARO-APOC3, ARO-ANG3, etc. They plan to run Phase 3 studies. But pricing? Not mentioned. They discuss fazirsiran with Takeda. Takeda is partner. Revenue recognition from Takeda collaboration: $128.4M to be recognized over next 2-3 years. That's a fixed amount, not per-unit. They discuss pulmonary programs, C3, etc. The question is about a business where price is fixed and volume is rising. In biotech, often licensing deals have milestones and royalties. But here, they sold royalty rights to Royalty Pharma. That is a one-time sale, not a per-unit rate. Maybe the "rate" is the royalty rate on olpasiran sales? But they sold that royalty interest, so they no longer earn per-unit. They got upfront and milestones. That's not a per-unit rate. Alternatively, consider the Takeda collaboration: They receive revenue for managing clinical trials? That's a fixed contract amount, not per-unit. The question asks: "does management describe a situation in which THE PRICE, RATE, OR FEE THE COMPANY EARNS ON A MEANINGFUL PART OF ITS BUSINESS IS ALREADY FIXED OR CONTRACTUALLY SET, while THE QUANTITY OF BUSINESS THE COMPANY CAN EARN THAT RATE ON IS CURRENTLY RISING OR ABOUT TO RISE" Look for any mention of a per-unit fee, like per patient, per dose, per subscription, etc. Not present. Maybe the "business" is the pipeline of drugs. But the rate is not fixed.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NOAH | Noah Holdings Limited | Q1 2024 | 2024-05-30 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| MNKD | MannKind Corporation | Q4 2023 | 2024-02-27 | C |
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| JLL | Jones Lang LaSalle Incorporated | Q3 2023 | 2023-11-02 | F |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| SLF | Sun Life Financial Inc. | Q1 2023 | 2023-05-12 | B |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| CEIX | CONSOL Energy Inc. | Q4 2022 | 2023-02-07 | B |
| CHE | Chemed Corporation | Q3 2022 | 2022-11-01 | B+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| KFY | Korn Ferry | Q4 2022 | 2022-06-22 | B |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| KIM | Kimco Realty Corporation | Q2 2018 | 2018-07-26 | B+ |
| HLX | Helix Energy Solutions Group, Inc. | Q1 2018 | 2018-04-24 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| FI | Fiserv, Inc. | Q4 2017 | 2018-02-27 | C |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FIX | Comfort Systems USA, Inc. | Q1 2017 | 2017-04-30 | A |
| ABR | Arbor Realty Trust, Inc. | Q4 2016 | 2017-03-03 | B+ |
| GPOR | Gulfport Energy Corporation | Q4 2016 | 2017-02-14 | A |
ABR · Q4 2016 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing the Agency Business servicing portfolio at $13.6 billion with a fixed 48 basis point weighted average servicing fee that is already contracted and recurring. They explicitly note the portfolio is growing through recent originations, including $700 million closed in December, which will drive higher servicing income in Q 1. Management states they expect the portfolio to generate over $65 million annually and references growth from 2015 levels, indicating the reported Q4 results reflect a lower average volume during the quarter while the settled economics now scale with the increasing volume arriving in Q1.
FIX · Q1 2017 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES The transcript shows management describing a situation where pricing is stable and contracts (backlog) lock in rates, while volume is rising through backlog growth and upcoming organic work. The Q1 results reflect lower seasonal volume, with the backlog supporting higher throughput ahead. This fits the criteria of settled rates on meaningful contracted business with 13% backlog increase driving volume step-up.
CHE · Q3 2022 → YESThe question is about whether management describes a situation where the price/rate/fee is already fixed, but the quantity/volume is rising, so results scale with volume. YES Management describes Medicare reimbursement rates as already fixed by regulation (CMS), with the volume side now rising through a first significant expansion of clinical staff and patient capacity since the pandemic, plus strengthening admissions and weekly ADC growth in the second half. The reported quarter reflects lower volume (ADC down 4.